William Blair Downgrades Pharmasset (VRUS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq slides to near one-month low as AI rout deepens
- U.S. producer prices rise by 1.3% month-on-month in September
- Brent steady as US weighs easing sanctions on global 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Tesla-SpaceX Merger could be announced before December, Barclays says
Tweet
Share
E-mailGet Alerts VRUS Hot Sheet
Price: $0.00 --0%
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Rating Summary:
3 Buy, 10 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 10 | New: 31
Join SI Premium – FREE
William Blair downgraded Pharmasset (NASDAQ: VRUS) from Outperform to Market Perform, price target raised from $108 to $137.
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday.
For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.
Shares of Pharmasset closed at $134.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- William Blair Downgrades Clarivate Analytics (CCC) to Market Perform
- KeyBanc Downgrades Cirrus Logic (CRUS) to Sector Weight
- William Blair Resumes Jasper Therapeutics (JSPR) at Outperform
Create E-mail Alert Related Categories
DowngradesRelated Entities
William BlairSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
